secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001104659-23-078184
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Priveterra (PMGM) stockholders approve AEON Biopharma merger; 1.68M shares redeemed
--------------------------------------------------------------------------------

- All proposals passed with ~97% of votes cast in favor (8,189,816 for, 239,010 against).
- 1,681,348 public shares (84% of outstanding) validly elected for redemption at trust value.
- Closing expected in July 2023, subject to satisfaction or waiver of conditions in the business combination agreement.
- Directors elected for New AEON board: Marc Forth, Jost Fischer, Eric Carter, Robert Palmisano, Shelley Thunen.
- Stockholders approved New AEON 2023 Incentive Award Plan and Employee Stock Purchase Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923078184/0001104659-23-078184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923078184/tm2320630d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-078184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer